Group 1 - The second batch of 249 Macau designated drugs has been approved for use in Hengqin, enhancing the availability of medications for Macau residents in the Guangdong-Macau Deep Cooperation Zone [1] - The first batch included 296 drugs approved for use in April 2024, bringing the total to 367 drugs and 545 specifications available for designated medical institutions [1] - The second batch includes medications for cardiovascular diseases, metabolic diseases, respiratory diseases, and infections, expanding the variety of available treatments [1] Group 2 - Gansu Province's drug regulatory authority has announced five typical cases of drug-related violations, emphasizing the enforcement of drug safety and health regulations [2] - Cases include the use of inferior drugs by a clinic and the sale of prescription drugs without a licensed pharmacist present [2] Group 3 - Six innovative drugs are proposed for inclusion in breakthrough therapy designations, including IN10018, MRG004A, ATG-022, LM-302, RC148, and BI 1810631, indicating ongoing advancements in drug development [3] - These drugs target various conditions, including cancer and other serious diseases, showcasing the focus on innovative therapies [3] Group 4 - Merck has received approval for a new 200-day dosing regimen for its antiviral drug Prevymis (Letermovir), aimed at preventing CMV infections in at-risk adult patients [4] Group 5 - Changchun High-tech's subsidiary has received approval for clinical trials of Cabergoline tablets, a dopamine receptor agonist for treating hyperprolactinemia, with no similar products currently on the market [5] - This approval is expected to facilitate the clinical development of the product to meet unmet medical needs [5] Group 6 - Tiantan Biological has completed Phase I clinical trials for its recombinant human coagulation factor VIII-Fc fusion protein, showing a significantly extended half-life compared to existing products [6] - The product currently has no domestic or imported competitors available [6] Group 7 - Iwubio has initiated Phase I clinical trials for its dermatitis diagnostic patch, which is designed to assist in diagnosing allergic contact dermatitis [7] - The product is classified as a Class 1 therapeutic biological product, with further clinical trials planned [7] Group 8 - Xinghao Pharmaceutical reported a 32.01% decline in net profit for the first half of 2025, with revenue of 308 million yuan, a decrease of 4.08% year-on-year [8] Group 9 - Nanwei Medical announced a 17.04% increase in net profit for the first half of 2025, with revenue of 1.565 billion yuan, reflecting a growth of 17.36% [9] - The company plans to distribute a cash dividend of 5.00 yuan per share to shareholders [9] Group 10 - Zhonghui Biological's stock surged over 160% on its first trading day, closing at 33.28 HKD per share, significantly above its IPO price of 12.9 HKD [10] - The company's market capitalization exceeded 13 billion HKD [10] Group 11 - Libo Bio has completed nearly 100 million yuan in Pre-A round financing, led by Tian Shili Capital and Panlin Capital, indicating strong investor interest in RNA-targeted drug development [11] Group 12 - Fosun Pharma has granted global development and commercialization rights for its investigational product XH-S004 to Expedition, with potential milestone payments totaling up to 6.45 billion USD [12] Group 13 - Peking University Medicine faces significant revenue and profit declines due to the termination of its long-term service contract with Peking University International Hospital, with projected losses of approximately 600 million yuan in sales and 40 million yuan in net profit [13] - The company is exploring new directions for transformation, but faces uncertainty regarding its future operations [13]

Core Viewpoint - Merck has received approval from the NMPA for a new 200-day dosing regimen of its non-nucleoside CMV inhibitor, Prevymis® (Letermovir), for adult patients at risk of late-onset CMV infection and disease following HSCT, extending the previous 100-day regimen [1][2]. Group 1: Product Approval and Implications - The new dosing regimen allows for the continued use of Prevymis® up to 200 days post-HSCT for adults, providing extended protection against CMV infection [1]. - Prevymis® was previously approved for use in CMV-seropositive adults and children over 6 months old, with a 100-day treatment duration post-HSCT [1]. - The approval of the 200-day regimen is expected to enhance clinical practices and support personalized CMV prevention strategies for patients [1]. Group 2: Industry Impact and Expert Opinions - CMV infection is a major complication for HSCT recipients, contributing to increased mortality rates associated with transplant procedures [2]. - The new 200-day regimen addresses a gap in CMV prevention management beyond the initial 100 days, offering a longer window of protection during immune reconstitution for adult patients [2]. - Merck's advancements in the anti-infective field are highlighted by the approval for extending the use of Prevymis® for both adult patients at risk and future approvals for pediatric patients [2].

Core Viewpoint - Merck has received approval from the National Medical Products Administration (NMPA) in China for its novel non-nucleoside cytomegalovirus (CMV) inhibitor, Prevymis® (Letermovir), in two formulations: oral tablets and injectable solution, for use in pediatric patients aged 6 months and older weighing at least 6 kg [1] Group 1 - The approved indications include prevention of CMV infection and disease in adult and pediatric recipients of allogeneic hematopoietic stem cell transplantation (HSCT) who are CMV seropositive [1]